期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

客观评价与量化使用非甾体消炎药的新工具：非甾体消炎药评分系统 被引量：5

原文传递
导出
摘要 非甾体消炎药（NSAIDs）在短时间内即可明显改善多数脊柱关节炎患者的临床症状，是目前治疗中轴型脊柱关节炎[包括强直性脊柱炎（AS）]的一线用药。有研究发现，NSAIDs对患者的某些炎性指标（如C反应蛋白）产生了虽然很弱但具有统计学意义的影响，
作者 朱剑 黄烽
机构地区 解放军总医院风湿科
出处 《中华内科杂志》 CAS CSCD 北大核心 2013年第4期282-284,共3页 Chinese Journal of Internal Medicine
关键词 非甾体消炎药 评分系统 强直性脊柱炎 关节炎患者 工具 量化 NSAIDS 脊柱关节炎
分类号 R979.5 [医药卫生—药品]
  • 相关文献

参考文献13

  • 1Dougados M, B6hier JM, Jolchine I,et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum, 2001,44 : 180-185.
  • 2Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis,2011,70:896-904.
  • 3Benhamou M, Gossec L, Dougados M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein. Rheumatology (Oxford) ,2010,49:536-541.
  • 4Wanders A, Heijde Dv, Landew6 R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical triM. Arthritis Rheum ,2005,52 : 1756-1765.
  • 5朱剑,黄烽.对非甾体消炎药延缓强直性脊柱炎结构破坏的再认识[J].中华内科杂志,2013,52(2):153-155. 被引量：7
  • 6Straube S, Trainer MR, Moore RA, et al. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol,2009,9:41.
  • 7朱剑,黄烽.选择性COX-2抑制剂临床应用新进展——解读2008年美国风湿病学会关于NSAIDs使用的白皮书[J].中国新药杂志,2009,18(6):497-501. 被引量：11
  • 8Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults : results of a US consensus panel of experts. Arch Intern Med, 2003,163:2716-2724.
  • 9朱剑,黄烽.重视环境因素对强直性脊柱炎病情与疗效的影响[J].中华内科杂志,2012,51(11):842-844. 被引量：9
  • 10Dougados M, Simon P, Braun J, et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/ epidemiological studies in axial spondyloarthritis. Ann Rheum Dis,2011,70:249-251.

二级参考文献41

  • 1BOMBARDIER C, LAINE L, REICIN A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group[ J]. N Engl J Med, 2000, 343(21 ) :1520 - 1528.
  • 2SCHNITZER TJ, BURMESTER GR, MYSLER E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TAR- GET), reduction in ulcer complications: randomised controlled trial[ J]. Lancet, 2004, 364(9435 ) :665 - 674.
  • 3SILVERSTEIN FE, FAICH G, GOLDSTEIN JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS stud- y: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study[ J]. JAMA, 2000, 284 (10) : 1247 - 1255.
  • 4LAINE L, CURTIS SP, CRYER B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison [ J ]. Lancet, 2007, 369 (9560) :465 - 473.
  • 5BRESALIER RS, SANDLER RS, QUAN H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma che- moprevention trial[ J ]. N Engl J Med, 2005, 352 (11 ) :1092 - 1102.
  • 6BERTAGNOLLI MM, EAGLE C J, ZAUBER AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas [ J ]. N Engl J Med, 2006, 355 ( 9 ) :873 - 884.
  • 7KEARNEY PM, BAIGENT C, GODWIN J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials [ J]. BMJ, 2006, 332 (7553) : 1302 - 1308.
  • 8MCGETTIGAN P, HENRY D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 [J]. JAMA, 2006, 296(13): 1633 -1644.
  • 9HINZ B, RENNER B, BRUNE K. Drug insight: cyclo-oxygenase-2 inhibitors a critical appraisal [ J ]. Nat Clin Pract Rheumatol, 2007, 3 (10) :552 - 560.
  • 10ZANCHETTI A, HANSSON L, DAHLOF B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group[ J]. J Hypertens, 2001, 19 (6) :1149 - 1159.

共引文献22

同被引文献46

引证文献5

二级引证文献19

中华内科杂志
2013年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部